Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on January 3, 2002, reporting on the significant divestiture of its oncology assets and related operations to OSI Pharmaceuticals, Inc. (OSI) effective December 21, 2001. This strategic move involved selling its pipeline of clinical-stage oncology products, intellectual property, and its Boulder, Colorado facilities. The transaction generated substantial immediate proceeds for Gilead, comprising $130.0 million in cash and OSI common stock valued at approximately $38.8 million. Furthermore, Gilead stands to receive up to an additional $30.0 million based on future development milestones for the oncology drug NX211. The company anticipates recording a significant one-time gain of approximately $155.4 million (net of taxes) in the fourth quarter of 2001 as a result of this sale. This divestiture reflects a strategic shift for Gilead, allowing it to focus resources on other therapeutic areas. The filing includes pro forma financial statements illustrating the impact of this transaction on the company's balance sheet and statements of operations as if the sale had occurred earlier.
Key Highlights
- 1Gilead Sciences completed the sale of its oncology business to OSI Pharmaceuticals on December 21, 2001.
- 2The sale included oncology product pipeline, intellectual property, and Boulder, Colorado operations.
- 3Gilead received $130 million in cash and $38.8 million in OSI common stock as consideration.
- 4An additional $30 million in potential milestone payments from OSI is possible.
- 5Gilead expects to record a pre-tax gain of approximately $155.4 million in Q4 2001 from the sale.
- 6The oncology business was not a reportable segment for Gilead.
- 7Pro forma financial statements are provided to show the impact of the divestiture.